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Background: Glycoprotein 2 (GP2) was discovered as the major autoantigen of Crohn’s disease (CD)-specific
pancreatic autoantibodies (PAB). We investigated anti-GP2 IgA and IgG antibodies as novel serological parameters
in CD and assessed their association with distinct disease phenotypes.
Methods: Anti-GP2 and anti-Saccharomyces cerevisiae (ASCA) IgA and IgG were detected by ELISA employing
recombinant human GP2 and phosphopeptidomannan, respectively and PAB by indirect immunofluorescence (IIF)
in 271 sera, 169 with CD and 102 with ulcerative colitis (UC). As healthy controls 160 adult blood donors and 65
children were included.
Results: Anti-GP2 IgG and/or IgA were more prevalent in CD (51/169, 30.2%) than in UC (9/102, 8.9%) patients and
in controls (9/225, 4%) (p < 0.001 respectively). ASCA IgG and/or IgA were present in 60/169 (35.5%) in CD and in 7/
102 (6.9%) in UC patients (p < 0.001). CD patients with ileocolonic location (L3) showed a significantly higher
prevalence of anti-GP2 and ASCA IgA and/or IgG (40/113 and 48/113, respectively; p < 0.05 for both comparisons),
whereas CD patients with colonic location (L2) revealed a significantly diminished prevalence for these
autoantibody specificities (2/32 and 5/32, respectively, p < 0.05 for both). Anti-GP2 IgG were significantly more
prevalent in CD patients with stricturing behaviour (B2) and perianal disease (7/11, p < 0.02) and less prevalent in
those with penetrating behaviour (B3) and perianal disease (4/31, p < 0.05). The occurrence of anti-GP2 IgA and/or
IgG was significantly more prevalent in CD patients with age at diagnosis of ≤16 years (16/31, p < 0.009). Prevalence
of one or more anti-GP2 or ASCA IgA and/or IgG was significantly higher in L3, B2, and A1 and lower in L2 (68/113,
27/41, 23/31, 6/32; p < 0.04, respectively).
Conclusions: Anti-GP2 IgG and IgA, constituting novel CD specific autoantibodies, appear to be associated with
distinct disease phenotypes identifying patients at a younger age, with ileocolonic location, and stricturing
behaviour with perianal disease.
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Table 1 Demographic and clinical characteristics of
patients with Crohn’s disease
CD (n = 169)
Female, n (%) 102 (60.3)
Median age at study (max,min) 36 (8,87)
Age at diagnosis (years)
below 17 years (A1), n (%) 31 (18.3)
between 17 and 40 years (A2), n (%) 19 (11.2)
above 40 years (A3), n (%) 119 (70.4)
Location
ileal (L1), n (%) 24 (14.,2)
colonic (L2), n (%) 32 (18.9)
ileocolonic (L3), n (%) 113 (66.9)
upper disease, modifier (L4), n (%) 12 (7.1)
Behavior
non-stricturing, non-penetrating (B1), n (%) 86 (50.9)
stricturing (B2), n (%) 41 (24.3)
penetrating (B3), n (%) 42 (24.8)
perianal disease modifier (p), n (%) 62 (36.7)
non-stricturing, non-penetrating (B1p), n (%) 20 (11.8)
stricturing (B2p), n (%) 11 (6.5)
penetrating (B3p), n (%) 31 (18.3)
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The most prevalent clinical entities of inflammatory
bowel disease (IBD), Crohn’s disease (CD) and ulcerative
colitis (UC), affect as many as one in 250 individuals
among Caucasians, and demonstrate an increase in other
ethnic populations [1-4]. Although the pathophysiology
of IBD is poorly understood, there is scientific evidence
demonstrating that a damaged mucosal barrier is leading
to mucosal inflammation triggered by intestinal bacteria
in genetically predisposed individuals [3,5]. The intes-
tinal inflammation in CD patients affects all layers of the
bowel wall and adventitia and in contrast to UC is not
confined to rectum and colon, but can be found
throughout the alimentary tract [1].
Immune responses to disease-specific autoantigens
also appear to be a prominent feature of CD, and are
possibly involved in the pathogenesis of IBD [3]. Glyco-
protein 2 (GP2) has recently been identified as the major
autoantigenic target of CD-specific pancreatic autoanti-
bodies (PAB) [6-8]. GP2 is mainly expressed as glycosyl
phosphoinositol (GPI) membrane-anchored protein in
the pancreas and released together with zymogens into
the duodenum upon hormonal or neuronal stimulation
[9,10]. Interestingly, GP2 has also been demonstrated to
be a membrane-anchored receptor of microfold cells (M
cells) in human intestinal Peyer’s patches (PP) and to be
over-expressed at the site of CD inflammation in con-
trast to UC [6,11]. GP2 is involved in transcytosis of bac-
terial antigens, the presentation of whom by dendritic
cells give rise to an antigen-specific immune response
[11]. GP2 interacts with epithelial and activated T cells,
binds to scavenger receptor on endothelial cells, and
modulates innate and adaptive immune responses sup-
porting a potential pathophysiological role [2,12].
Patients with IBD demonstrate disease-specific anti-
bodies that may aid in the differential diagnosis of IBD, es-
pecially in the case of unclassified IBD [13,14]. Antibodies
to bacterial peptides and glycans have been considered
diagnostic markers of IBD but their prognostic signifi-
cance is a matter of debate [15-17]. While the diagnostic
significance of anti-GP2 antibodies in IBD has been stud-
ied in some detail, the clinical significance of these auto-
antibodies is unclear [2,18-21]. Thus, it is currently
unknown whether humoral autoreactivity to GP2 or PAB
respectively may assist in the prediction or stratification of
disease activity or whether these autoantibodies are asso-
ciated with specific clinical features [2,19,21-23].
The aim of the present study was to investigate the as-
sociation of anti-GP2 antibodies with disease character-
istics in CD in comparison with anti-Saccharomyces
cerevisiae antibodies (ASCA), an established serological
marker of CD. Here, we provide evidence for the first
time that humoral autoreactivity to GP2 in CD appears
to be associated with distinct clinical phenotypes.Methods
Patient population
Serum samples from 169 patients with CD (median of
age: 36 years) and 102 patients with UC were collected
at the Children’s hospital of the Technical University
Dresden, at the Department of Gastroenterology, Hepa-
tology, and Infectious Diseases of the Otto-von-Guericke
University Magdeburg, and at the Department of
Gastroenterology and Clinical Nutrition, University Col-
lege Hospital, London. All samples were taken at the
time of consent and enrolment. Demographic and clin-
ical characteristics of patients with CD are shown in
Table 1. In total, 225 controls (median of age: 35 years,
min 9 months, max 85 years) were recruited: 165 healthy
adult blood donors and 65 children, who were admitted
for eye surgery correcting their strabismus but were
otherwise healthy. As control group for the comparison
with patients with onset of disease below 17 years, the
65 children of the control group (median of age: 6 years,
min 9 months, max 16 years) were selected.
Patients with CD were assigned a behavioural pheno-
type according to the Montreal classification [24].
Patients with unclassified IBD were excluded from the
study. Correctness of diagnosis had been confirmed for
all patients by 3 investigators (UA, AF, and MWL). Me-
dian age of patients with UC was 47 years (minimum 17,
maximum 92) and 57 from 102 patients were female
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standard clinical, radiological, endoscopical and histo-
logical criteria [25,26].
The study was approved by the local ethics commit-
tees and conducted in accordance with the Helsinki dec-
laration. Written informed consent was obtained from
each individual. Aliquots of serum samples have been
stored at −80 °C until use.Detection of antibodies to GP2 by ELISA
Anti-GP2 (IgA and IgG) autoantibodies were detected in
sera of patients employing an ELISA from Generic
Assays (Dahlewitz/Berlin, Germany), in accordance with
the manufacturer’s instructions. This ELISA is based on
recombinant human GP2 expressed in Spodoptera frugi-
perda 9 cells as solid-phase antigen [18]. For expression
of GP2 by the baculovirus system, the plasmid
pcDNA3.1+GP2-trunc-Thrombin-His is used which
codes the amino acid sequence of GP2 isoform
BAA88166 (pancreatic zymogen granule membrane
associated protein GP2 alpha form) corresponding to
the official isoform 2 (NP_001493) without 8 amino
acids at the N-terminal end [27].
The anti-GP2 IgG ELISA displayed an intra-assay vari-
ability of 5.7% and an inter-assay variability of 5.0% for
sera with elevated concentrations of 24.3 U/ml and
26.9 U/ml, respectively. The anti-GP2 IgA ELISA
revealed an intra-assay variability of 5.9% and an inter-
assay variability of 5.0% for sera with an elevated con-
centration of 17.8 U/ml and 18.5 U/ml, respectively. The
functional assay sensitivities for anti-GP2 IgG and IgA
determined as described elsewhere were assessed at
2.4 U/ml and 1.8 U/ml, respectively [28].Detection of antibodies to Saccharomyces cerevisiae by
ELISA
In view of published studies reporting the frequent co-
occurrence of CD-specific autoantibodies like PAB or in
particular anti-GP2 and ASCA, and in order to compare
anti-GP2 with ASCA, serum samples from patients were
also tested for this anti-microbial reactivity. ASCA were
determined as described previously, employing commer-
cially available ELISA (ASCA IgA, ASCA IgG, GA Gen-
eric Assays GmbH, Dahlewitz, Germany) according to
the recommendations of the manufacturer as reported
elsewhere [13].
The intra-assay coefficient of variation was 2.0% for a
sample containing 76 U/ml and 2.8% for a sample con-
taining 78 U/ml of ASCA IgA and ASCA IgG, respect-
ively. The inter-assay coefficient of variation was 5.9%
for a sample containing 72 U/ml and 1.8% for a sample
containing 81 U/ml of ASCA IgA and ASCA IgG,
respectively.Assessment of pancreatic antibodies (PAB)
Antibodies to exocrine pancreas were detected by run-
ning patient samples on commercially available pancreas
tissue sections according to the recommendations of the
manufacturer (GA Generic Assays GmbH, Dahlewitz,
Germany). Briefly, tissue sections were incubated in a
moist chamber at RT for 30 minutes with 50 μl of seri-
ally diluted serum, starting at a dilution of 1 in 20 as
reported elsewhere [18].
Samples were subsequently washed, embedded, and
analysed with the automated interpretation system
AKLIDES 40 (Medipan, Dahlewitz/Berlin, Germany) as
described for other IIF tests [29]. Samples with a titre of
1:20 were considered borderline and samples with a titre
of 1:40 or higher were scored positive.
Statistical analysis
A Kolmogorov-Smirnov test was used to analyse the data
for normality. Differences between groups were tested by
Kruskal-Wallis and Fisher’s exact test with two-tailed
probability. Spearman’s rank correlation test was applied
for within group comparison. P values < 0.05 were consid-
ered significant. Assay performance including sensitivity,
specificity, positive and negative likelihood ratio and
receiver-operating characteristics (ROC) curve analysis
were determined using Medcalc statistical software (Med-
calc, Mariakerke, Belgium). The measured values were
expressed as medians with 95% confidential intervals (CI).
Results
Patient cohorts
To investigate humoral autoreactivity to GP2 in IBD,
271 patients with IBD (169 CD patients, 102 UC
patients) and 225 controls were included into this multi-
centre study with one British and two German gastro-
enterology departments. Patient characteristics are
depicted in Table 1.
Comparison of antibodies to GP2 with PAB in IBD
patients and controls
Recombinant human GP2 immobilised on microtiter
plates was employed to detect anti-GP2 IgG and IgA
antibodies in sera of 169 patients with CD, 102 patients
with UC and 225 controls (Table 2).
There was a significantly higher prevalence of anti-
GP2 IgA (22/169, 13%), IgG (48/169, 28.4%) and IgA
and/or IgG (51/169, 30.2%) in CD patients compared to
UC patients (2/102, 2.0%; 8/102, 7.8%; 9/102, 8.8%, re-
spectively) and in controls (3/225, 1.3%; 6/225, 2.7%; 9/
225, 4%; respectively) in accordance to the Kruskal-
Wallis test (p = 0.001, respectively).
Prevalence rates for anti-GP2 IgA [7/66 (10.6%) vs 15/
103 (14.6%)] and IgG [16/66 (24.2%) vs 32/103 (31.1%)]
as well ASCA IgA [16/66 (24.2%) vs 23/103 (22.3%)] and
Table 2 Antibody distribution in 169 patients with Crohn’s disease (CD), 102 patients with ulcerative colitis (UC), and
225 controls
CD UC controls
All CD patients (n = 169) ASCA negative CD patients (n = 109) (n = 102) (n = 225)
Anti-GP2 IgA, (%) 22 (13.0) 9 (8.2) 2 (2.0) 3 (1.3)
Anti-GP2 IgG, (%) 48 (28.4) 25 (22.9) 8 (7.8) 6 (2.7)
Anti-GP2 IgA and/or IgG, (%) 51 (30.2) 26 (23.9) 9 (8.8) 9 (4.0)
PAB>= 1/20, (%) 74 (43.8) 45 (41.3) 24 (23.5) nd
PAB>= 1/40, (%) 65 (38.5) 38 (34.9) 21 (20.6) nd
ASCA IgA, (%) 39 (23.1) - 3 (2.9) 2 (0.9)
ASCA IgG, (%) 48 (28.4) - 5 (4.9) 7 (3.1)
ASCA IgA and/or IgG, (%) 60 (35.5) - 7 (6.9) 8 (3.5)
ASCA and/or anti-GP2, (%) 86 (50.9) - 15 (14.7) 16 (7.1)
Number of positive antibodies
detected by ELISA
0 83 (49.1) 83 (76.1) 87 (85.3) 208 (92.4)
1 40 (23.7) 18 (16.5) 12 (11.8) 13 (5.8)
2 28 (16.6) 8 (7.3) 3 (2.9) 4 (1.8)
3 11 (6.5) - 0 (0.0) 0 (0.0)
4 7 (4.1) - 0 (0.0) 0 (0.0)
ASCA, antibody to mannan of Saccharomyces cerevisiae; CI, confidence interval; GP2, zymogen granule membrane glycoprotein 2; nd, not done; PAB, pancreatic
autoantibody.
Bogdanos et al. BMC Gastroenterology 2012, 12:102 Page 4 of 9
http://www.biomedcentral.com/1471-230X/12/102IgG [17/66 (25.8%) vs 31/103 (30.1%)] were not signifi-
cantly different comparing German and English patients
with CD, respectively. Pancreatic autoantibodies detected
by IIF also demonstrated a higher prevalence in CD com-
pared to UC patients [65/169 (38.5%) vs 21/102 (20.6%);
p < 0.003] and were significantly correlated with anti-GP2
IgG (Spearman’s coefficients of rank correlation [rho] =
0.466, 95% interval of confidence [CI]: 0.367–0.554,
p < 0.001). However, in UC patients the prevalence of PAB
at titres ≥1:40 was significantly higher (21/102, 20.6%)
compared to anti-GP2 IgG (8/102, 7.8%) and even with
anti-GP2 IgG and/or IgA (9/102, 8.8%) (p< 0.02 and
p< 0.03, respectively). In CD patients the difference in the
occurrence of PAB≥ 1:40 (65/169, 38.5%) and anti-GP2
(IgG: 48/169, 24.8% IgG and/or IgA: 51/169, 30.2%) did
not reach significance (p= 0.064 and p=0.108, respect-
ively). There is good accordance between anti-GP2 and
anti-PAB positivity. From 51 CD patients with anti-GP2
IgA and/or IgG positivity 45 (88%) showed also PAB posi-
tivity. Conversely, from 65 patients with PAB positivity 20
were negative for both anti-GP2 IgA and IgG respectively.
Comparison of antibodies to GP2 with ASCA in IBD
patients
To compare anti-GP2 reactivity with an established anti-
body marker in IBD patients, ASCA IgA and IgG were
determined in both patient cohorts. Like anti-GP2 anti-
bodies, ASCA IgA (39/169, 23.1%), IgG (48/169, 28.4%),
and IgA and/or IgG (60/169, 35.5%) demonstrated asignificantly higher prevalence in CD than in UC patients
[3/102 (2.9%), 5/102 (4.9%), 7/102 (6.9%), respectively;
p < 0.001, for all comparisons] and in controls (Table 2).
Receiver operating characteristics curve analysis revealed
similar AUC values for the detection of ASCA and anti-
GP2 isotypes (Figure 1). Only the comparison of anti-GP2
IgA and ASCA IgG showed significantly different areas
under the curve (AUC) values (difference between areas:
0.0886, 95% CI: 0.0105–0.167; p < 0.03).
IgA and IgG reactivity to GP2 and Saccharomyces cere-
visiae were significantly correlated (rho= 0.422, 95% CI:
0.340–0.533; rho = 0.335, 95% CI: 0.225 to 0.436, p < 0.001,
respectively). However, 26 (23.9%) of ASCA negative
patients demonstrated either IgA or IgG reactivity to GP2
(Table 2).
Assay performance characteristics for anti-GP2, ASCA, and
PAB
Assay performance characteristics for the detection of
anti-GP2 IgA and IgG were compared to corresponding
ASCA and PAB values and the results are summarized
in Table 3. Regarding the serological discrimination of
CD and UC, ASCA and anti-GP2 antibodies alone have
medium positive likelihood ratios (LR) indicating the
ratio between the probability of a positive test result
given the presence of the disease (+LR) and the prob-
ability of a positive test result given the absence of the
disease (-LR). Interestingly, PAB demonstrated an even
lower +LR despite the higher prevalence in CD patients.
Figure 1 Receiver-operating characteristic (ROC) curve analysis
of anti-GP2 IgA. Receiver-operating characteristic (ROC) curve
analysis of anti-GP2 IgA and IgG as well as ASCA IgA and IgG
detected in 169 CD patients and 102 UC patients: The area under
the curve (AUC) was 0.652, 0.682, 0.713, and 0.743 for anti-GP2 IgA,
anti-GP2 IgG, ASCA IgA, and IgG, respectively. The AUC values were
significantly different for the comparison of anti-GP2 IgA and ASCA
IgG (p = 0.0262). All other AUC values were not significantly different.
dashed line - ASCA IgG. solid line - ASCA IgA. dashed dotted line -
anti-GP2 IgG. dotted line - anti-GP2 IgA.
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sessment improves the +LR values regarding the sero-
logical differentiation of CD and UC. The detection of at
least 2 ELISA-antibodies thereof reveals a +LR for CD of
9.2. Only 3/102 (2.9%) patients suffering from UCTable 3 Performance characteristics of anti-GP2 and ASCA IgA
patients
sensitivity 95% CI specificity
anti-GP2 IgA 13.0 8.3–19.0 98.0
anti-GP2 IgG 28.4 21.7–35.8 92.2
anti-GP2 IgA or IgG 30.2 23.4–37.7 91.2
ASCA IgA 23.1 17.0–30.2 97.1
ASCA IgG 28.4 21.7–35.8 95.1
ASCA IgA or IgG 35.5 28.3–43.2 93.1
PAB ≥1/20 45.4 37.6–53.4 76.5
PAB ≥1/40 38.5 31.1–46.2 79.4
at least 1 ab* 50.9 43.1–58.6 85.3
at least 2 ab* 27.2 20.7–34.6 97.1
at least 3 ab* 10.6 6.4–16.3 100.0
at least 4 ab* 4.1 1.7–8.3 100.0
Sensitivity, specificity and likelihood ratios were calculated using a cut-off of 20 U/m
ab, antibody; ASCA, antibody to mannan of Saccharomyces cerevisiae; CD, Crohn’s d
zymogen granule membrane glycoprotein 2; LR, likelihood ratio; PAB, pancreatic audisplayed antibody reactivities scoring positive in two of
the four ELISAs. The determination of 3 or more anti-
bodies seen in 18/169 CD patients is highly specific for
CD (100%) resulting in an infinite +LR.Association of anti-GP2 and ASCA with location of disease
Employing the Montreal classification of IBD, CD
patients were stratified according to age at diagnosis, lo-
cation, and behaviour of disease (Table 1). Fisher’s exact
test revealed a significantly higher prevalence of IgA
and/or IgG reactivity to GP2 (40/113, 35.4%) in CD
patients with ileocolonic location of disease (L3) (11/56,
19.6%; p < 0.05) (Table 4).
In contrast, there was a significantly lower prevalence
thereof in CD patients characterized by a colonic loca-
tion of disease (L2) [2/32 (6.2%) vs 49/137 (35.8%);
p < 0.001]. A similar pattern was seen for ASCA IgA
and/or IgG [L3: 48/113 (42.5%) vs 12/56 (21.4%); L2: 5/
32 (15.6%) vs 55/137 (40.1%); p < 0.001, p < 0.02; respect-
ively). While a significantly lower prevalence in CD
patients with L2 was also detected for anti-GP2 IgA [0/
32 (0.0%) vs 22/132 (16.7%)], anti-GP2 IgG [2/32 (6.2%)
vs 46/137 (33.5%)], and the simultaneous appearance of
both isotypes [2/32 (6.2%) vs 49/137 (35.8%)], only the
occurrence of anti-GP2 IgG was significantly higher in
CD patients with L3 [38/113 (33.6%) vs 10/56 (17.9%)]
(Table 4). In contrast, the increased prevalence of PAB
in CD with L3 [49/113 (43.4%) vs 16/56 (28.6%)] did not
reach significance and only the occurrence thereof in
CD with L2 was significantly reduced [7/32 (21.9%) vs
58/137 (42.3%); p < 0.05]./IgG and PAB investigating 169 CD patients and 102 UC
95% CI +LR 95% CI -LR 95% CI
93.0–99.8 6.6 1.6–27.4 0.9 0.8–1.0
85.1–96.6 3.6 1.8–7.3 0.8 0.7–0.9
83.9–95.9 3.4 1.8–6.6 0.8 0.7–0.9
91.6–99.4 7.8 2.5–24.7 0.8 0.7–0.9
88.9–98.4 5.8 2.4–14.1 0.8 0.7–0.8
86.4–97.2 5.2 2.5–10.9 0.7 0.6–0.8
67.0–84.3 1.9 1.3–2.8 0.7 0.6–0.8
70.3–86.8 1.9 1.2–2.9 0.8 0.7–0.9
76.9–91.5 3.5 2.1–5.6 0.6 0.5–0.7
91.6–99.4 9.2 3.0–29.0 0.8 0.7–0.8
96.4–100.0 ∞ 0.9 0.8–0.9
96.4–100.0 ∞ 1.0 0.1–1.0
l for all ELISA and a titre of 1/20 and 1/40 of IIF.
isease; CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; GP2,
toantibody; UC, ulcerative colitis; *anti GP2 and/ or ASCA.
Table 4 Association of anti-GP2, ASCA, and PAB with disease characteristics in CD: p values for elevated (bold) or
diminished (italic) prevalence of samples with anti-GP2, ASCA, or PAB in 169 CD patients detected by ELISAs and IIF,
respectively
anti-GP2 ASCA PAB
IgA IgG IgA or IgG IgA and IgG IgA IgG IgA or IgG IgA and IgG >=1/20 >=1/40
L1
L2 <0.02 <0.002 <0.001 <0.03 <0.02 <0.05








A1 <0.004 <0.009 <0.001 <0.004 <0.002 <0.001
A2
A3 <0.02
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disease
Crohn’s disease patients with penetrating disease (B3)
demonstrated a significantly lower prevalence of anti-
GP2 IgG alone and of anti-GP2 IgA and/or IgG [6/42
(14.3%) vs 42/127 (33.1%) and 7/42 (16.7%) vs 44/127
(34.6%); p < 0.02, p < 0.04, respectively] (Table 4). The
diminished appearance of anti-GP2 IgA (4/42, 9.5%) did
not reach significance. Interestingly, CD patients with
stricturing and perianal disease (B2p) showed an ele-
vated occurrence of anti-GP2 IgG alone and of anti-GP2
IgA and/or IgG [7/11 (63.6%) vs 41/158 (25.9%) and 7/
11 (63.6%) vs 44/158 (27.8%); p < 0.02, respectively].
Interestingly, there was also a significant lower preva-
lence of anti-GP2 IgG in CD patients with penetrating
and perianal disease [4/31 (12.9%) vs 44/138 (31.9%),
p < 0.05]. In contrast, there was no significant association
for ASCA and PAB with disease behaviour detectable.
Apart from a significantly higher prevalence of CD
specific IgG in patients with B2p (9/11, 81.8%) compared
to IgA (2/11, 18.2%; p < 0.03), there was no further dif-
ference in the isotype prevalence regarding anti-GP2 or
ASCA.
Association of anti-GP2 and ASCA with age at diagnosis
Crohn’s disease patients with an age less than 17 years at
diagnosis (A1) demonstrated a significantly higher
prevalence of CD-specific IgG antibodies [anti-GP2 IgG
16/31 (51.6%) vs 32/138 (23.2%), ASCA IgG 15/31
(48.4%) vs 33/138 (23.9%), PAB 22/31 (71.0%) vs 43/138
(31.2%); p < 0.004, p < 0.004, p < 0.001, respectively].
Interestingly, the combination of IgA and/or IgG to GP2also revealed a significantly higher prevalence in CD
patients with A1 [16/31 (51.6%) vs 35/138 (25.4%),
p < 0.009]. Remarkably, CD specific IgG occurred less
prevalent in CD patients with an age at diagnosis above
40 years [anti-GP2 IgG: 2/19 (10.5%) vs 46/150 (30.7%);
ASCA IgG: 4/19 (21.1%) vs 44/150 (29.3%)], however,
only the less prevalent appearance of PAB reached sig-
nificance in this patient group [2/19 (10.5%) vs 63/150
(42.0%); p < 0.02]. Although anti-GP2 IgA was more
prevalent in CD patients with A1 than ASCA IgA [10/31
(32.3) vs 9/31 (29.0%)] and less in CD patients with A3
(1/19, 5.3% vs 2/19, 10.5%), all prevalence rates were not
significantly different compared with the respective pa-
tient groups regarding age at diagnosis. To exclude a
possible bias regarding higher prevalence of antibody oc-
currence in younger individuals, we selected a group of
controls with an age below 17 years. There were no sig-
nificant different prevalences of CD specific antibodies
compared to the 160 adult blood donors. However, the
prevalence of CD specific antibodies was significantly
higher in the CD patient group consisting of 31 indivi-
duals with A1 than in this particular control group [anti-
GP2 IgA: 10/31 (32.3%) vs 1/65 (1.5%), anti-GP2 IgG 16/
31 (51.6%) vs 2/65 (3.1%), ASCA IgA: 9/31 (29.0%) vs 1/
65 (1.5%), ASCA IgG 15/31 (48.4%) vs 1/65 (1.5%);
p < 0.001, respectively].
Association of the combined analysis of anti-GP2 and
ASCA with disease phenotypes
Positivity for antibodies to GP2 or Saccharomyces cere-
visiae in at least one of the four ELISAs investigated was
significantly associated with ileocolonic disease location
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behaviour [27/41 (65.9%) vs 59/128 (46.1%); p < 0.04],
and age at diagnosis below 17 years [23/31 (74.2%) vs
63/138 (45.7%), p < 0.006] in CD patients (Table 5). Oc-
currence of at least one positive antibody was signifi-
cantly less prevalent in CD patients with colonic
location [6/32 (18.8%) vs 80/137 (58.4%); p < 0.001]. Re-
markably, the highly specific occurrence of three or
more antibodies in CD (n = 18) was significantly asso-
ciated with ileocolonic disease location [16/113 (14.2%)
vs 2/56 (3.6%); p < 0.04] and young age (A1) in CD [7/31
(22.6%) vs 11/138 (8.0%); p < 0.03].Discussion
The major findings of the present study are that anti-
GP2 antibodies are present in approximately 30% of
patients with CD, and appear to identify cases with an
earlier onset, ileocolonic location, and stricturing behav-
iour with perianal disease. Our findings support the no-
tion that anti-GP2 antibodies are diagnostically and
clinically-relevant markers of CD and can assist physi-
cians in the management of patients with clinical suspi-
cion of IBD. Not only anti-GP2 antibody testing by
ELISA shows a remarkable positive correlation with PAB
by IIF but also appears to allow better discrimination of
low titre or borderline positive PAB by IIF and seems
therefore more specific for CD than PAB testing. This
supports the notion that anti-GP2 antibody detection
can be a supplementary tool for the testing of CD-Table 5 Association of number of anti-GP2 and/or ASCA
antibodies in one sample with disease characteristics in
CD: p values for elevated (bold) or diminished (italic)
prevalence of samples with differing numbers of anti-
GP2 and/or ASCA in 169 CD patients detected by ELISAs
with a cut-off of 20 U/ml
Number of antibodies detected by ASCA and anti-GP2 ELISA
at least one at least two at least three Four
L1









A1 <0.006 <0.007 <0.03 <0.003
A2
A3specific pancreatic antibodies complementing or even
replacing the laborious IIF technique [2].
Cohorts from clinical centres recruiting patients par-
ticipating in the present study reported a ~30% anti-GP2
seropositivity in patients with CD [18-20]. However, ac-
curate estimation of the overall prevalence of anti-GP2
antibodies in patients with IBD could not be carried out
up so far, as testing of serum samples was performed in
different laboratories and at various time points [18-20].
The systematic approach used in the present study,
employing simultaneous testing of all coded samples in
one laboratory and by the same immunodiagnostician
(DRo), allowed for continuity of testing, thus permitting
safer conclusions regarding the exact frequency of anti-
GP2 antibodies in IBD. The approximately 30% anti-
GP2 seropositivity rate may indeed be an underestima-
tion of the real prevalence in newly diagnosed cases with
CD, if antibodies are diminished over the course of the
disease as an effect of the administration of biological
agents and immunosuppressive treatment for CD
[2,18,19]. In fact, sharp decline of IgG anti-GP2 anti-
bodies has been described in CD during a 12-month
course with infliximab. Intriguingly, such conversion
from seropositivity to seronegativity was not accompan-
ied by simultaneous reduction of ASCA [19].
An experienced group of Investigators from Belgium
have tested 164 patients with CD for anti-GP2 anti-
bodies, using the commercially-available assay which
was used in the present study [21]. Op De Beéck et al.
reported a sensitivity of anti-GP2 antibodies in patients
with CD of 21%. However, it is not clear at what time
points these serum samples were tested for autoantibody
reactivity [21]. Also, the overall prevalence of PAB in the
Belgian CD cohort was significantly lower than that of
the present study (31% vs. 44%), and therefore a lower
prevalence of anti-GP2 in the Belgian IBD population
was not a surprising finding. The strikingly negative cor-
relation between lower gastrointestinal tract localization
of Crohn’s disease and presence of anti-GP2 was a char-
acteristic feature of both studies. Finally, Op De Beéck
et al. have failed to associate anti-GP2 seropositivity with
other clinical correlates, when we have found that the
presence of these antibodies is more prevalent in
patients who present with CD at a younger age, in
addition to those with stricturing disease behaviour. Im-
mediate comparisons of the statistical values amongst
the two studies cannot be made, as the Belgian study has
been published in the form of a short Letter to the Edi-
tor with limited access to the wealth of the statistical
analyses’ data [19]. Even if there was a consensus
amongst the two studies, it would be very premature to
comment on the clinical significance of anti-GP2 anti-
bodies in IBD, as the clinical relevance of these anti-
bodies cannot be assessed based on two studies. Care
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regarding the effect of biological agents in the behaviour
of anti-GP2 antibodies as the Belgian investigators did
not find a profound effect of infliximab and adalimumab
in patients followed up for 6–44 months [19,21].
Exchange of serum samples among researchers and
large, multi-centre, prospective studies are needed to
better delineate the diagnostic and clinical relevance of
anti-GP2 pancreatic antibodies and their behaviour over
the course of the disease in patients with inflammatory
bowel diseases.
The development of a commercially-available ELISA
based on recombinant human GP2 will allow for the ac-
curate detection of GP2-specific pancreatic autoanti-
bodies in routine laboratory practice and the initiation
of longitudinal studies [18]. It would be of interest to
know whether such studies will provide independent
verification of the thesis supported by the present data
that combined anti-GP2 and ASCA testing performs
better than relying on tests limited to ASCA alone.
Conclusions
Anti-GP2, constituting novel CD specific autoantibodies,
is positive in about 30% of patients with CD and their
detection may be of clinical significance. Anti-GP2 IgG
and IgA, constituting novel CD specific autoantibodies,
appear to be associated with distinct disease pheno-
types identifying patients at a younger age, with ileoco-
lonic location, and stricturing behaviour with perianal
disease.
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